Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

2019471 citationsJournal Articlegreen Open Access

Authors

Krishnansu S. Tewari · University of California, Irvine Medical Center

Robert A. Burger · University of Pennsylvania

Danielle Enserro · Roswell Park Comprehensive Cancer Center

Barbara M. Norquist · University of Washington

Elizabeth M. Swisher · University of Washington

Mark F. Brady · Roswell Park Comprehensive Cancer Center

Michael A. Bookman

Abstract

No survival differences were observed for patients who received bevacizumab compared with chemotherapy alone. Testing for <i>BRCA1/2</i> mutations and homologous recombination deficiency is essential.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 37, Issue 26, pp. 2317-2328

DOI: 10.1200/jco.19.01009

Field-Weighted Citation Impact: 53.24